Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Potential new Alzheimer's drugs advancing in clinical trials

08.04.2010
After years of preparation and anticipation, scientists who discover and develop new medications are about to answer a key question about Alzheimer's disease: Will drugs that block formation of abnormal clumps of protein in the brain called amyloid-beta slow the progression of the devastating disease?

The cover story in the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine, assesses the scientific foundation and clinical landscape of those amyloid-beta blockers.

C&EN Senior Editor Lisa Jarvis notes that amyloid-beta is at the heart of a central hypothesis — and simmering controversy — about Alzheimer's disease. Some scientists are convinced that amyloid-beta is the root cause of the nerve-cell death and subsequent mental decline in individuals with Alzheimer's disease.

Others think that something else, perhaps a still-unidentified environmental neurotoxin, is the real culprit. That mystery agent, they suspect, triggers formation of beta-amyloid.

If the clinical trials are successful, doctors within 5-10 years could have an arsenal of new drugs that can slow the progression of Alzheimer's. If the trials fail, its back to the drawing board to find new hypothesis and drug targets for the disease, the article notes.

Michael Bernstein | EurekAlert!
Further information:
http://www.acs.org

More articles from Life Sciences:

nachricht Tarantula Toxin is Used to Report on Electrical Activity in Live Cells
21.10.2014 | Marine Biological Laboratory

nachricht Built-in-billboards: Male bluefin killifish signal different things with different fins
21.10.2014 | University of Illinois at Urbana-Champaign

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Meine Daten – deine Daten?

21.10.2014 | Veranstaltungen

2. Coaching-Kongress: Coaching heute: Zwischen Vertraulichkeit und Firmeninteressen

21.10.2014 | Veranstaltungen

Sägen ohne Späne: Treffen der Kristallspezialisten am Fraunhofer CSP

21.10.2014 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Digitale Agenda: Unternehmen brauchen schnelle und sichere Netze

21.10.2014 | Studien Analysen

Stuttgarter Forschergruppe entdeckt molekulares Quantenbit mit langer Kohärenzzeit

21.10.2014 | Informationstechnologie

Wie wirksam sind Anti-Aging-Produkte? Lasertechnologie erleichtert Tests der Kosmetikindustrie

21.10.2014 | Medizintechnik